Eur Rev Med Pharmacol Sci 2022; 26 (7): 2216-2216
DOI: 10.26355/eurrev_202204_28446

Author Correction: Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

L. Monzo, C. Gaudio, F. Cicogna, C. Tota, V. Petronilli, S. Mennuni, E. De Ruvo, L. Calò

Department of Cardiology, Policlinico Casilino, Rome, Italy


Correction to: European Review for Medical and Pharmacological Sciences 2021; 25 (18): 5690-5700–DOI: 10.26355/eurrev_202109_26788–PMID: 34604961, published online on 30 September 2021.

After publication, the authors applied to change the first two lines of Table II as the second column results were erroneously shifted in the first column. In this way, the results were quite difficult to understand.

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.

Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

Free PDF Download

To cite this article

L. Monzo, C. Gaudio, F. Cicogna, C. Tota, V. Petronilli, S. Mennuni, E. De Ruvo, L. Calò
Author Correction: Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 7
Pages: 2216-2216
DOI: 10.26355/eurrev_202204_28446